CaliPharms, Inc.

CaliPharms, Inc.

KGET
CaliPharms, Inc.US flagOther OTC
0.00
USD
- -
- -
474,349.00Market Cap
CaliPharms, Inc.
KGET
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
TTM
FRC
- -
- -
- -
Revenue per Share
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
- -
- -
-0.01
Book Value per Share
- -
- -
- -
Tangible Book Value per Share
- -
2,262
3,205
Basic Weighted Avg Shares
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
-731.04
Operating Margin (%)
- -
- -
- -
Depreciation Expense
- -
- -
-6
Net Income, GAAP
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-5,677.83
Profit Margin (%)
- -
- -
-9
Working Capital
- -
- -
- -
LT Debt
- -
- -
-9
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'14
Jun'14
Sep'14
ST Debt
1
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,048
3,079
3,363
Market Capitalization
20
11
2

Working Capital

FRC

in mil. unless spec.
Mar'14
Jun'14
Sep'14
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
4
9
Payables & Accruals
3
3
3
ST Debt
1
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-13.31%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
Business
CaliPharms, Inc. (KGET) engages in the medicinal cannabis industry in the United States, with a primary focus on the development and wholesale distribution of THC and CBD-infused beverages and concentrate powders. The company offers proprietary all-natural, organic THC and CBD powder concentrates produced through a specialized extraction process featuring active carbon filtration and ion exchange resins for purity and consistency; these products undergo batch testing by independent California labs for pesticides, heavy metals, residual solvents, and cannabinoid content, targeting applications in beverages, coffees, cookies, drinks, and candies with precise milligram dosing. It operates through its 51%-owned subsidiary Country Junction Farms, Inc., a permitted medical cannabis cultivator in California, and pursues expansion into supporting sectors of the legalized cannabis market. Founded as a Delaware corporation in 2008 through the conversion of predecessor entities dating back to 1996, CaliPharms is headquartered at 33175 Temecula Parkway, Suite A 8019, Temecula, California 92592. The company, previously known as Kleangas Energy Technologies, Inc., underwent a name change to CaliPharms, Inc. in January 2017 to reflect its strategic pivot to the cannabis sector. In recent developments, CaliPharms entered the wholesale medical cannabis distribution market by launching its THC and CBD powder offerings and initiating discussions with High Performance Beverage Co. (OTC Pink: TBEV) as its first customer. It executed a term sheet and completed the acquisition of Pacific Cannabis Growers, a medical cannabis farm in Humboldt County, California, securing a 10,000 square foot mixed-light commercial cultivation permit for year-round automated greenhouse production; this followed its prior acquisition of a controlling interest in Country Junction Farms. No significant funding rounds, new product launches, or operational expansions have been reported in the last 1-2 years, with the company maintaining its focus on California-based medicinal cannabis activities amid low trading volume and minimal recent disclosures.